Dr Daniel Petrylak Explains PD-1, PD-L1 Expression in Bladder Cancer Treatment

PD-L1 Expression in Bladder CancerПодробнее

Dr. Daniel Petrylak on Early Trials for a New Urothelial Bladder Cancer TreatmentПодробнее

Daniel P. Petrylak, MD, regarding PD-L1 biomarkers in the treatment of bladder cancerПодробнее

The basic biology of PD-1/PD-L1Подробнее

Dr. Petrylak on Immunotherapy for Second-line Treatment in Bladder CancerПодробнее

Anti-Correlation Between KLRG1 and PD-1 in Tumor CD8 T Cells | OncotargetПодробнее

Dr. Necchi on Impact of PD-1 Inhibition in Bladder CancerПодробнее

Improving anti-PD-1/PD-L1 therapy for localized bladder cancerПодробнее

Treatment of Bladder Cancer-Immune Checkpoint InhibitorsПодробнее

Checkpoint Inhibitors for NMIBCПодробнее

Dr. Sharma on PD-L1 as Biomarker for Immunotherapy in Bladder CancerПодробнее

Dr. Balar on PD-L1 Testing for Urothelial CancerПодробнее

What is PD1 and PDL1 in Kidney Cancer?Подробнее

Dr. Petrylak on Novel Immunotherapy Research in Bladder CancerПодробнее

Meet Oncologist Daniel Petrylak, MDПодробнее

Dr. Brahmer Explains PD-1 and PD-L1Подробнее

PD-L1 in Metastatic Bladder Cancer - Bladder Cancer Video LibraryПодробнее

Dr. Daniel Petrylak on the IMvigor Study of Atezolizumab in Advanced Bladder CancerПодробнее

Dr. Petrylak on Immunotherapy in Bladder CancerПодробнее